eye disease
Treatment for serious eye disease approved in Scotland
June 12, 2025Market Access, Marketing Services, Research and Development, Sales and Marketing LYTENAVA, Opthalmology, Scottish Medicines Consortium, clinical programme, european union, eye disease, market approval, strategic partnership, united kingdom, wet age-related macular degeneration
Outlook Therapeutics has announced the Scottish Medicines Consortium (SMC) approval of Lytenava (bevacizumab gamma) for the treatment of wet age-related …
Successful trial results announced for potential rare eye disease treatment
April 14, 2025Research and Development Eyestem, Opthalmology, age-related macular degeneration (AMD), biotech, cell therapy, eye disease
Eyestem Research, an Indian biotech company, announced successful results from its phase 1 trial of Eyecyte-RPE, a potential therapy for …
Novartis’ Lucentis secures European approval for infants with rare eye disease
September 6, 2019Medical Communications, Sales and Marketing Europe, Lucentis, Novartis, eye disease, pharma
Novartis has made the surprise announcement that its VEGF inhibitor Lucentis (ranibizumab) has been awarded marketing authorisation from the European …
Dompé gives the FDA its first approved neurotrophic keratitis treatment
August 24, 2018Medical Communications, Sales and Marketing Dompe, FDA, Oxervate, eye disease, pharma
Milan-based biotech firm Dompé has revealed that the FDA has awarded approval in the US to its Oxervate (cenegermin-bkbj ophthalmic …
Latest content
Scots neonatal innovations target hearing loss and earlier care
August 28, 2026
Agentis Health Group acquires Clinical Pharmacist Solutions
August 26, 2026
